Clinical trial · Observational
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
NCT06238284CI-TRIAL-00073558unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| HER2 Expression | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cervical Cancer Group
- interventionNames
- Other: no intervention
- label
- Endometrial Cancer Group
- interventionNames
- Other: no intervention
- label
- Ovarian Cancer Group
- interventionNames
- Other: no intervention
Primary outcomes (1)
- measure
- HER2 status
- timeFrame
- from 2023.07 to 2024.05
- description
- HER2 exprssion level evaluated by pathologists
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with primary gynecological malignant tumor confirmed by histopathology * Women aged 18-75 * The expected survival time is greater than 12 weeks * KPS \> 60, ECOG score is 0-2 * All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up Exclusion Criteria: * Pregnant and lactating women * Suffering from other malignant tumors in the past 5 years * Patients who are not suitable for this study according to the investigator's judgment
References
Publications (0)
Data not yet available
No reference posted for this study.